| Literature DB >> 22615773 |
Hillary S Hayden1, Regina Lim, Mitchell J Brittnacher, Elizabeth H Sims, Elizabeth R Ramage, Christine Fong, Zaining Wu, Eva Crist, Jean Chang, Yang Zhou, Matthew Radey, Laurence Rohmer, Eric Haugen, Will Gillett, Vanaporn Wuthiekanun, Sharon J Peacock, Rajinder Kaul, Samuel I Miller, Colin Manoil, Michael A Jacobs.
Abstract
Burkholderia pseudomallei, the etiologic agent of human melioidosis, is capable of causing severe acute infection with overwhelming septicemia leading to death. A high rate of recurrent disease occurs in adult patients, most often due to recrudescence of the initial infecting strain. Pathogen persistence and evolution during such relapsing infections are not well understood. Bacterial cells present in the primary inoculum and in late infections may differ greatly, as has been observed in chronic disease, or they may be genetically similar. To test these alternative models, we conducted whole-genome comparisons of clonal primary and relapse B. pseudomallei isolates recovered six months to six years apart from four adult Thai patients. We found differences within each of the four pairs, and some, including a 330 Kb deletion, affected substantial portions of the genome. Many of the changes were associated with increased antibiotic resistance. We also found evidence of positive selection for deleterious mutations in a TetR family transcriptional regulator from a set of 107 additional B. pseudomallei strains. As part of the study, we sequenced to base-pair accuracy the genome of B. pseudomallei strain 1026b, the model used for genetic studies of B. pseudomallei pathogenesis and antibiotic resistance. Our findings provide new insights into pathogen evolution during long-term infections and have important implications for the development of intervention strategies to combat recurrent melioidosis.Entities:
Mesh:
Year: 2012 PMID: 22615773 PMCID: PMC3352902 DOI: 10.1371/journal.pone.0036507
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
B. pseudomallei isolates used for whole genome comparison.
| Clinical features | |||||||||||
| Isolate | Year | Time between isolates (mo) | ST | Specimen location | Age (yr) | Sex | Symptom duration | Diabetes | Other risk factor | Organs involved | Blood culture |
| 1026a | 1993 | 102 | Pus | 29 | F | 14 | Yes | No | Skin, soft tissue, spleen, joint | Pos | |
| 1026b | 1993 | 0 | 102 | Blood | |||||||
| 1258a | 1994 | 221 | Sputum | 72 | M | 10 | Yes | No | Lung | Neg | |
| 1258b | 1995 | 6 | 221 | Blood | |||||||
| 1710a | 1996 | 177 | Blood | 52 | M | 7 | Yes | No | Lung, soft tissue abscess | Pos | |
| 1710b | 1999 | 30 | 177 | Blood | |||||||
| 1106a | 1993 | 70 | Liver pus | 21 | F | 3 | No | Thalassaemia | Liver | Neg | |
| 1106b | 1996 | 36 | 70 | Liver pus | |||||||
| 354a | 1988 | 78 | Sputum | 65 | M | 9 | No | No | Lung | Neg | |
| 354e | 1994 | 75 | 78 | Sputum | |||||||
Multilocus sequence types (ST) categorize strains based on variations in DNA sequence of seven housekeeping genes [19].
Clinical details are provided for the primary episode for each patient.
Days of symptoms prior to presentation at the hospital.
Figure 1Schematic circular diagrams of the large and small chromosomes of the 1026b genome.
Rings from outside to inside: scale with tick marks positioned every 200 Kb, annotated forward CDS and reverse CDS colored-coded by COG functional categories (Table S1), pseudogenes (olive), genomic islands (red), IS elements (blue), rRNA and tRNA (green), GC% plot and (G – C)/(G + C) deviation plot.
Genomic islands in B. pseudomallei 1026b.
| Island | Locus tags | Size (kb) | Mobility-related genes | GC (%) | Genes in K96243 genomic islands (shared/total) | Presence in other completed genomes | Functional note |
| 1 | BP1026B_I0126-BP1026B_I0181 | 40.5 | 1 Int | 64.8 | GI2 42/48 GI15 28/43 | + | Prophage |
| 2 | BP1026B_I1081-BP1026B_I1137 | 42.7 | 1 Int | 63.5 | – | – | Prophage |
| 3 | BP1026B_I1268-BP1026B_I1271 | 4.7 | 1 Int | 61.0 | – | – | Hypothetical proteins |
| 4 | BP1026B_I1319-BP1026B_I1320 | 1.1 | 2 Tnp | 61.1 | – | + | Transposases |
| 5 | BP1026B_I1584-BP1026B_I1662 | 90.8 | 3(1) Tnp | 62.0 | GI8 55/57 | + | Transport proteins, outer membrane proteins and transcriptional regulators |
| 6 | BP1026B_I2008-BP1026B_I2017 | 10.4 | 3 Tnp | 53.1 | – | + | Hypothetical proteins |
| 7 | BP1026B_I2085-BP1026B_I2161 | 54.5 | 1 Int | 60.8 | – | + | phi1026b |
| 8 | BP1026B_I2478-BP1026B_I2482 | 12.5 | 0 | 60.6 | – | + | Hemolysin activator protein precursor and haemagluttinin repeat protein |
| 9 | BP1026B_I2589-BP1026B_I2592 | 1.5 | 1 Tnp | 60.0 | GI5 3/9 | + | Putative plasmid replication protein |
| 10 | BP1026B_I2779-BP1026B_I2784 | 8.2 | 1 Int, 2 Tnp | 49.8 | – | – | XRE family transcriptional regulator and plasmid recombination enzyme |
| 11 | BP1026B_I2942-BP1026B_I2943 | 4.5 | 0 | 55.0 | – | – | Putative ATP binding protein and hypothetical protein |
| 12 | BP1026B_I3340-BP1026B_I3346 | 4.7 | 0 | 59.6 | – | – | Prophage proteins |
| 13 | BP1026B_I3580-BP1026B_I3637 | 43.4 | 1 Int, 1 Tnp | 63.6 | GI2 34/48 GI15 26/43 | + | Prophage |
| 14 | BP1026B_II0077-BP1026B_II0080 | 5.8 | 1 Tnp | 55.1 | – | + | Putative ABC transport proteins |
| 15 | BP1026B_II0420-BP1026B_II0449 | 28.8 | 2 Int, 7(2) Tnp | 57.5 | – | – | XRE family transcriptional regulator and hypothetical proteins |
| 16 | BP1026B_II2203-BP1026B_II2252 | 62.1 | 2 Int, 6(1) Tnp | 59.2 | GI16 21/37 | + | Metabolic island |
| 17 | BP1026B_II2392-BP1026B_II2393 | 1.1 | 0 | 50.1 | – | – | Hypothetical proteins |
Integrase and transposase are abbreviated as Int and Tnp, respectively. Partial genes and pseudogenes are indicated in parentheses.
Other completed genomes are 1710b, 1106a and 668.
Summary of whole genome variation in the five B. pseudomallei isolate pairs.
| Isolate pairs | # SNPs | # Indels | Structural variants | Chromosome |
| 1026a-1026b | 0 | 0 | None | - |
| 1258a-1258b | 0 | 0 | 330 Kb Deletion | 2 |
| 1710a-1710b | 2 | 14 | 22 Kb Tandem repeat | 2 |
| 1106a-1106b | 5 | 41 | None | - |
| 354a-354e | 8 | 2 | 800 Kb Inversion | 2 |
1258a, 1710a and 354e exhibited the structural variant noted.
SNPs found in the 354, 1106 and 1710 isolate pairs.
| Reference locus | Isolate | S/NS | AA | AA in | AA/Total | SIFT | Gene product | Protein function |
| BPSL0042 | 354e | NS | Cys | Arg | 361/670 | T | Type III DNA modification methyltransferase | Defense mechanism |
| BPSL1768 | 354a | S | - | 1107/1281 | - | Cobaltochelatase (CobN) | Vitamin B12 metabolism | |
| BPSL2301 | 1710b | S | - | 35/898 | - | Pyruvate dehydrogenase subunit E1 (AceE) | Energy production | |
| BPSL2706 | 354e | NS | Lys | Thr | 271/532 | D | Putative lipoprotein | - |
| BPSL3027 | 1106b | S | - | 142/504 | - | DP-N-acetylmuramoyl-L-alanyl-D-glutamate synthase (MurD) | Cell envelope biogenesis | |
| BPSL3288 | 354e | NS | Leu | Pro | 216/276 | D | 5,10-methylenetetrahydrofolate reductase (MetF) | Methionine metabolism |
| BPSL3389 | 1106b | NS | Val | Ala | 886/1309 | D | Trifunctional transcriptional regulator/proline dehydrogenase (PutA) | Energy production |
| BPSL3390 | 1106b | S | - | 645/780 | - | Primosome assembly protein (PriA) | DNA replication | |
| BPSS0289 | 354e | - | - | - | - | - | Hypothetical protein | - |
| BPSS0571 | 1106b | S | - | 76/117 | - | Hypothetical protein | - | |
| BPSS0946 | 354e | - | - | - | - | - | β-lactamase (PenA) | Defense mechanism |
| BURPS1106A_1241 | 1106b | NS | His | Arg | 45/178 | - | Hypothetical protein | - |
| BPSS1483 | 354e | NS | Phe | Leu | 41/344 | D | TetR family protein | Transcriptional regulation |
| BPSS1483 | 1710a | NS | Asp | Tyr | 53/344 | D | TetR family protein | Transcriptional regulation |
| BPSS1995 | 354e | NS | Thr | Ala | 58/475 | T | Signal transduction histidine kinase (IrlS2) | Signal transduction |
SNP is located 112 bp upstream of BPSS0289.
SNP is located 78 bp upstream of penA.
SNPs are predicted to be deleterious (D) or tolerated (T) with regard to protein function.
Nonsynonymous mutations in BPSS1483 homologs from 107 B. pseudomallei isolates.
| Nucleotide change | Amino acid change | Strain | Present in primary | Present in relapse | Predicted effect on protein function |
| C70T | Q24Stop | 770 | N | Y | Stop |
| C160T | R54C | 242, 1350 | N, N | Y, Y | D |
| T185G | L62R | 1428 | N | Y | D |
| G307T | E103Stop | 1686 | N | Y | Stop |
| G351A | W117Stop | 479 | N | Y | Stop |
| G358T | E120Stop | 479 | Y | N | Stop |
| T500C | L167P | Pakistan 9 | Y | - | D |
| G539A | W180Stop | 986a | Y | - | Stop |
| C647T | A216V | 668 | Y | - | - |
| C686T | A229V | 1655 | Y | - | - |
| C691G | Q231E | 1119, 1210, 1069c | Y, Y, Y | Y, Y, - | - |
| G695A, C696T | G232D | 1119, 1210, 1069c | Y, Y, Y | Y, Y, - | - |
| G703C | E235Q | 668, 305 | Y | - | - |
| A709G | T237A | 668 | Y | - | - |
| G712A | A238T | 305, 1069c | Y, Y | -, - | - |
| G838A | G280S | 668, 406e, Pasteur 52237, 1373c | Y, Y, Y, Y | -, -, -, - | - |
| A893G, T894C | D297G | 1069c | Y | - | - |
| C904T | P302S | 658 | Y | Y | - |
| C973T | P325S | 668, 305 | Y, Y | -, - | - |
| T979A | S327T | 305 | Y | - | - |
| C982T | S328P | 305 | Y | - | - |
| A988G | T330G | 305 | Y | - | - |
Sequence chromatograms showed peaks for both the reference and SNP bases at this position in relapse isolates.
For isogenic pairs only.
SNPs introduced a stop codon (Stop) or were predicted to be deleterious (D) with regard to protein function. Prediction was not possible in the second half of the gene due to gaps in sequence alignments.
Antibiotic susceptibility of B. pseudomallei and B. thailandensis strains.
| MIC (ug/ml) | ||||||||||
| TZ | CL | IP | MC | MP | OF | PP | TC | TS | XL | |
|
| ||||||||||
| 1026b | 1.5 | 8 | 0.38 | 0.75 | 1.5 | 2 | 1 | 1.5 | 0.25 | 1 |
| 354b | 2 | 12 | 0.5 | 1.5 | 1.5 | 3 | 2 | 2 | 0.38 | 2 |
| 354e | 6 | >256 | 1.5 | 6 | 6 | >32 | 4 | 4 | 3 | 4 |
|
| ||||||||||
| E264 | 1.5 | 8 | 0.38 | 1 | 1 | 1.5 | 2 | 3 | 0.75 | 3 |
| TnBTH_I3273 | 1.5 | 8 | 0.38 | 4 | 1 | 3 | 2 | 64 | 1.5 | 3 |
| TnBTH_II0885 | 1.5 | 8 | 0.38 | 2 | 1 | 1.5 | 2 | 64 | 1.5 | 6 |
Antimicrobial agent abbreviations: TZ, ceftazidime; CL, chloramphenicol; IP, imipenem; MC, minocycline; MP, meropenem; OF, ofloxacin; PP, piperacillin; TC, tetracycline; TS, trimethoprim/sulfamethoxazole (1/19); and XL, amoxicillin/clavulanic acid (2/1). For TS and XL, numbers in parentheses indicate the ratio of drugs in the combination, and the MIC value refers to the first component.
Detection limits of the assays.
Figure 2Fosmid tilings from 1258a and 1258b spanning the location of the 330 Kb deletion.
Tilings of 1258a (top) and 1258b (bottom) fosmids against the 1026b reference genome as shown. Sequence coordinates of 1026b chromosome 2 appear along the top horizontal line below which three black lines indicate 1x, 2x and 3x fosmid coverage. Two additional horizontal black lines visually separate coverage lines from clone positions, which are represented by rectangles. Four colors within each rectangle illustrate features of the clone position as described in Hayden et al. [21]. Blue dots at the lower left and right edges of rectangles symbolize the x and y fosmid paired-end sequences aligned to the 1026b sequence. In 1258a, five clones (yellow first quarter) spanned the deletion breakpoint and flanked a large coverage gap in the tiling. The x (at 2.0 Mb) and y (at 1.7 Mb) anchored positions of a single clone are circled. In contrast, clones from 1258b tiled throughout this region indicating that there is no deletion in this isolate.
Figure 3Depth of coverage of 1710a Sanger sequence reads and fosmids across chromosome 2.
The number of 1710a sequence reads (red) and fosmids (blue) was counted in 500 bp and 10 Kb sliding windows, respectively, along chromosome 2 of the complete 1710b reference sequence. The spike in coverage of fosmids and sequence reads between 200 and 400 Kb is due to the tandem repeat of 17 genes. The smaller spike of sequence reads between 1800 and 2000 Kb is the result of a repeat of the Rhs element Vgr protein gene BURPS1710b_A0207.